Journal of International Psychiatry

Depression and schizophrenia are the most common psychiatric disorders, and their precise neurobiology have yet to be elucidated. Accumulating evidence suggests that inflammation plays a key role in the pathophysiology of depression and schizophrenia, and anti-inflammatory drugs have a certain therapeutic effect on mental diseases. Epoxy-fatty acids, which have anti-inflammatory effects, such as epoxyeicosatrienoic acids, can be broken down by soluble epoxide hydrolase into idols with lower biological activity. Inhibition of sEH has obvious anti-inflammatory properties in the central nervous system. This review focuses on ‘soluble epoxide hydrolase-inflammation-epoxyeicosatrienoic acid’, analyzes the role of sEH in the arachidonic acid metabolism pathway and the progress of sEH in the study of psychiatric disorders, in order to explore new therapeutic target for mental disorders and the clinical value of sEH inbitors as therapeutic or prophylactic drugs.

Soluble epoxide hydrolase; Depression; Schizophrenia; Inflammatory; Epoxyeicosatrienoic acid